NBP(NovaBridge Biosciences) 的内部人交易:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 交易日 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-11-18 | Hagler Mark Arnold | Chief Commercial Officer | 公开市场买入 | 184,000 | $0.38 |
| 2026-11-17 | Hagler Mark Arnold | Chief Commercial Officer | 公开市场买入 | 46,000 | $0.34 |
| 2026-09-18 | Dennis Phillip Andrew | Chief Medical Officer | 公开市场卖出 | 8,209 | $0.71 |
| 2026-09-09 | Cao Sean Wuxiong | Chief Bus. Development Officer | 公开市场卖出 | 107,978 | $0.74 |
| 2026-08-31 | Xu Cong Claire | EVP, Clinical Development | 公开市场卖出 | 3,282 | $0.79 |
| 2026-07-06 | Xu Cong Claire | SVP, Clinical Development | 公开市场卖出 | 4,485 | $0.89 |
| 2026-06-18 | Dennis Phillip Andrew | Chief Medical Officer | 公开市场卖出 | 8,494 | $0.66 |
| 2026-06-01 | Xu Cong Claire | SVP, Clinical Development | 公开市场卖出 | 3,494 | $3.94 |
| 2026-05-14 | Cao Sean Wuxiong | See Remarks | 公开市场卖出 | 21,399 | $1.99 |
| 2026-04-24 | Hagler Mark Arnold | See Remarks | 公开市场买入 | 230,000 | $2.51 |